ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Zynquista approved in EU for certain patients with type I diabetes
April 29, 2019Sanofi has announced that its joint SGLT1/SGLT2 inhibitor with Lexicon, Zynquista (sotagliflozin), has been approved in Europe for certain patients with type I diabetes. -
FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
January 24, 2019The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of ... -
FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes
May 31, 2018The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabete
Pharma Sources Insight January 2025
